<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922895</url>
  </required_header>
  <id_info>
    <org_study_id>UTSW_092012-012</org_study_id>
    <secondary_id>U01AA021893-01</secondary_id>
    <nct_id>NCT01922895</nct_id>
  </id_info>
  <brief_title>Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis</brief_title>
  <acronym>NTAH-Mod</acronym>
  <official_title>Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out whether a diet supplemented with a probiotic nutrient
      can improve alcoholic hepatitis and gut complications compared to routine standard care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: Evaluate the effects of probiotic supplements on improvement in MELD score and gut
      mucosal integrity in patients with MELD &lt; 21. Patients will be randomized to receive daily
      probiotics for 6 months and standard of care treatment or placebo with standard care.

      Aim 2: Document the natural history of moderately severe alcoholic hepatitis. Patients who
      decline randomization will be offered the option of inclusion in the study prospectively for
      data collection purposes and research study procedures.

      Aim 3: Create a data and tissue biorepository. This biorepository will serve as a national
      resource for studies related to acute alcoholic hepatitis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MELD score</measure>
    <time_frame>30 days</time_frame>
    <description>MELD scoring system for assessing the severity of chronic liver disease; MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6[Ln serum creatinine (mg/dL)] + 6.4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MELD score</measure>
    <time_frame>180 days</time_frame>
    <description>Improvement in MELD score over 180 day study duration.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gut mucosal permeability</measure>
    <time_frame>180 days</time_frame>
    <description>Gut mucosal permeability will be measured by changes from baseline in the gut mucosal integrity as assessed by the lactulose/mannitol test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Acute Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Placebo for Probiotic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus Rhamnosus GG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus Rhamnosus GG</intervention_name>
    <description>Probiotic nutritional supplement; Lactobacillus Rhamnosus GG</description>
    <arm_group_label>Lactobacillus Rhamnosus GG</arm_group_label>
    <other_name>Culturelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Probiotic</intervention_name>
    <description>Capsule manufactured without active ingredients.</description>
    <arm_group_label>Placebo for Probiotic</arm_group_label>
    <other_name>Dummy capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to provide informed consent by subject or appropriate family member

          2. Age between 21-70 years

          3. Recent alcohol consumption &gt; 50 g/d for &gt; 6 months, continuing within two months
             before enrollment

          4. At least 2 of the following symptoms or signs of acute alcoholic hepatitis: Anorexia,
             nausea, RUQ pain, jaundice, leukocytosis, hepatomegaly AND

          5. Elevation of AST &gt; 80 U/L, but &lt; 500 U/L at the time of admission or within 3 days of
             baseline visit; AST &gt; ALT and ALT &lt; 200 U/L; total bilirubin &gt; 3 mg/dL AND

          6. Liver biopsy showing alcoholic hepatitis (steatohepatitis) OR ultrasound of liver
             showing increased echogenicity OR CT scan showing decreased attenuation of liver
             compared to spleen OR MRI showing fatty liver (decreased signaling intensity on T1
             weighted images). If the liver biopsy (done within 60 days of inclusion) confirms
             diagnosis of AAH then inclusion e will be waived.

          7. Model for End-Stage Liver Disease (MELD) &lt;20

          8. Willingness to utilize two reliable forms of contraception (both males and females of
             childbearing potential) from screening through the first six weeks of study.

        Exclusion Criteria:

          1. Hypotension with BP &lt; 80/50 after volume repletion

          2. Pregnancy; incarceration; inability to provide consent or lack of appropriate family
             member

          3. Signs of systemic infection: Fever &gt; 38o C and positive blood or ascites cultures on
             appropriate antibiotic therapy for &gt; 3 days within 3 days of inclusion

          4. Acute gastrointestinal bleeding requiring &gt; 2 units blood transfusion within the
             previous 4 days

          5. Undue risk from immunosuppression: Positive HBsAg; a positive skin PPD skin test or
             history of treatment for tuberculosis; history of any malignancy including
             hepatocellular carcinoma; known HIV infection

          6. Treatment with corticosteroids or other immunosuppressive medications including
             specific anti-TNF therapy (not including pentoxifylline), calcineurin inhibitors for &gt;
             3 days within the previous 3 months.

          7. Evidence of acute pancreatitis: CT evidence and/or amylase or lipase &gt; 5 X upper limit
             of normal

          8. Serious cardiac, respiratory or neurologic disease or evidence of autoimmune
             hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilsons disease,
             hemochromatosis, secondary iron overload due to chronic hemolysis, alpha-1-antitrypsin
             deficiency

          9. Acute or chronic kidney injury with serum creatinine &gt; 3.0 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mack C Mitchell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>U Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mack C Mitchell, M.D.</last_name>
    <phone>214-645-8300</phone>
    <email>Mack.Mitchell@UTSouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blair Holbein, PhD</last_name>
    <phone>214-648-5009</phone>
    <email>Blair.Holbein@UTSouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig J McClain, MD</last_name>
      <phone>502-852-6991</phone>
    </contact>
    <investigator>
      <last_name>Craig J McClain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur J McCullough, MD</last_name>
      <phone>216-444-2766</phone>
    </contact>
    <investigator>
      <last_name>Arthur J McCullough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mack C Mitchell, M.D.</last_name>
      <phone>214-645-8300</phone>
      <email>Mack.Mitchell@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Mack C Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Mack Mitchell</investigator_full_name>
    <investigator_title>Professor, Vice-Chair Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Alcoholic Hepatitis</keyword>
  <keyword>MELD &lt; 20</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Nutritional Supplement</keyword>
  <keyword>Lactobacillus Rhamnosus GG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

